Skip to main content
Bio-Thera Solutions, Ltd. logo

Bio-Thera Solutions, Ltd. — Investor Relations & Filings

Ticker · 688177 ISIN · CNE100003R98 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 691 across all filing types
Latest filing 2021-10-25 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688177

About Bio-Thera Solutions, Ltd.

https://www.bio-thera.com/

Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.

Recent filings

Filing Released Lang Actions
百奥泰 第一届监事会第二十次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution passed at the 20th meeting of the first Supervisory Board of 百奥泰生物制药股份有限公司. It details the meeting's attendance, the discussion and approval of a related-party construction contract, and the voting results. It does not contain financial statements, audit opinions, or detailed financial data. It is a formal announcement of a board/management decision related to corporate governance and related-party transactions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or a notice of report publication, so it is not RPA or RNS.
2021-10-25 Chinese
百奥泰 独立董事关于第一届董事会第三十次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is an independent director's pre-approval opinion regarding a related party transaction to be discussed at a board meeting. It references compliance with company law and stock exchange listing rules, and it concerns a construction contract with a related party. The document is short (507 characters) and does not contain financial statements or detailed financial data. It is not a full report but rather a board/management related announcement about governance and approval of transactions. Therefore, it fits best under Board/Management Information (MANG).
2021-10-25 Chinese
百奥泰 自愿披露关于BAT7104注射液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by 百奥泰生物制药股份有限公司 regarding the approval of a clinical trial for their drug BAT7104 injection by the National Medical Products Administration (国家药监局). It contains no financial data, no financial statements, no management discussion of financial results, nor any regulatory certifications or voting results. The document is an announcement of a regulatory approval related to clinical trials, which is a regulatory update but does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it does not mention any report being attached or published. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial approval and risk disclosures, which do not fit other specific categories.
2021-10-19 Chinese
百奥泰 关于公开招标结果暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the results of a public tender and related party transaction involving the company 百奥泰生物制药股份有限公司. It details the tender process, the winning bidder (a related party), the transaction amount, and the need for board and shareholder approval. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal disclosure of a specific transaction and its procedural context, not a financial report or earnings release. It fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about a related party transaction and tender results that does not fall under more specific categories like Capital/Financing Update or M&A Activity.
2021-10-11 Chinese
《百奥泰生物制药股份有限公司章程》(2021年9月修订)
Governance Information Classification · 95% confidence The document is a detailed corporate charter or articles of association for 百奥泰生物制药股份有限公司 (Bio-Thera Solutions, Ltd.). It includes chapters on general provisions, business scope, share issuance, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial and audit matters, notices and announcements, mergers, disputes, amendments, and appendices. The content is focused on the company's governance structure, shareholder rights, board responsibilities, and procedural rules for meetings and corporate actions. There is no indication that this is an annual report, earnings release, or any financial statement. Instead, it is a governance document outlining the company's internal rules and regulations. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content support this classification with high confidence.
2021-09-28 Chinese
百奥泰 关于完成经营范围工商变更登记暨修订《公司章程》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 百奥泰生物制药股份有限公司 regarding the completion of a business scope change registration and the revision of the company's articles of association (公司章程). It details the approval of these changes by the board and shareholders, the completion of the registration with the market supervision authority, and the specific amendments made to the articles of association. There is no financial data, no mention of annual or interim reports, earnings, or other financial disclosures. The document is a formal announcement about corporate governance changes related to business scope and company bylaws, not a full governance report or management report. It fits best as a Regulatory Filing (RNS) because it is a regulatory announcement about corporate changes that do not fall under other specific categories like MANG (board/management changes) or CGR (governance information). The document length is short and it is an announcement, not a full report.
2021-09-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.